Cell Therapeutics reaches agreement with government

Cell Therapeutics has reached agreement with the federal government to pay $10.5 million to resolve the investigation of its business practices in marketing the cancer drug Trisenox (arsenic trioxide).

James G. Dickinson

March 1, 2007

5:00 am

Cell Therapeutics has reached agreement with the federal government to pay $10.5 million to resolve the investigation of its business practices in marketing the cancer drug Trisenox (arsenic trioxide). Cell Therapeutics sold Trisenox to Cephalon to finance other drug development efforts.

From the March 01, 2007 Issue of MM+M - Medical Marketing and Media

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.